Sunday, August 28, 2016

IntelGenx has positive pilot study with montelukast film

IntelGenx has positive pilot study with montelukast film

August 22, 2016 by · Leave a Comment 

Tweet IntelGenx (OTCQX:IGXT; TSX-V:IGX) has completed a pilot clinical study for montelukast VersaFilm that demonstrated a significantly improved pharmacokinetic profile against the reference product. Montelukast is a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer’s disease. The study data confirmed that buccal absorption […]

Profound Medical names Arun Menawat as CEO

Profound Medical names Arun Menawat as CEO

August 15, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) appointed Arun Menawat as its new CEO.  Steven Plymale, the company’s current CEO, will transition to President and COO. Dr. Menawat has been a member of Profound’s board since October 2014. Most recently, he was president and CEO of Novadaq Technologies, which pioneered the field of fluorescence imaging in the operating […]

Leerink reiterates rating on Aurinia following trial results

Leerink reiterates rating on Aurinia following trial results

August 15, 2016 by · Leave a Comment 

Tweet Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the reported top-line results with voclosporin in a Phase 2b clinical study in patients with active lupus nephritis. Analyst Joseph Schwartz writes that the study met its primary endpoint of complete remission and improvements in partial remission versus placebo. While efficacy was higher […]

Microbix sees record sales in fiscal 2016

Microbix sees record sales in fiscal 2016

August 15, 2016 by · Leave a Comment 

Tweet Microbix Biosystems (TSX:MBX) expects continued strong sales performance in the fourth quarter based on significant shipments in July and strong customer orders for delivery in the current quarter, which supports an earlier projection of record sales for the current fiscal year ending Sept. 30, 2016. “I am pleased with the strong sales of virology […]

Mackie starts Profound Medical at speculative buy

Mackie starts Profound Medical at speculative buy

August 10, 2016 by · Leave a Comment 

Tweet Mackie Research Capital initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and 12-month target price of $3.30. The stock was quoted at $1.45 at mid-day on Wednesday. “Relative to all approved prostate cancer treatments, we believe TULSA-PRO can clearly be differentiated with its clean safety profile, as well as decent efficacy,” […]

Antibe posts positive Phase 2 results in OA

Antibe posts positive Phase 2 results in OA

August 8, 2016 by · Leave a Comment 

Tweet Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) reported positive results from a Phase 2 study of ATB-346 in osteoarthritis (OA). Twelve patients with OA of the knee were treated once daily for 10 days with ATB-346 at a dose of 250 mg, a dose that contains one-sixth of the typical daily dose of naproxen for treating OA. […]

IntelGenx sells Forfivo XL royalty

IntelGenx sells Forfivo XL royalty

August 6, 2016 by · Leave a Comment 

Tweet IntelGenx (OTCQX:IGXT; TSX-V:IGX) has sold its royalty on future sales of Forfivo XL to SWK Holdings for $6-million. Forfivo XL (bupropion extended release) is the first 450-milligram bupropion hydrogen chloride tablet indicated for major depressive disorder approved by the FDA. Patent protection for Forfivo XL in the U.S. expires in 2027, with an authorized […]

Roth downgrades TearLab to neutral

Roth downgrades TearLab to neutral

August 4, 2016 by · Leave a Comment 

Tweet Roth Capital Partners downgraded TearLab (NASDAQ:TEAR; TSX:TLB) to “neutral” from “buy,” citing sales transition challenges. The stock closed at 83 cents on Wednesday. Analyst Chris Lewis writes that TearLab’s second quarter year-over-year growth of 9% was the lowest since the first quarter of 2012, prompting the company to once again lower its 2016 outlook. […]

Echelon starts Medical Facilities at buy

Echelon starts Medical Facilities at buy

August 2, 2016 by · Leave a Comment 

Tweet Echelon Wealth Partners initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and one-year price target of $22.50. The stock closed at $21.50 on Monday. Medical Facilities (MFC) is a physician-owned specialty surgical hospital and ambulatory surgery center owner-operator. “At current levels and after considering current dividend yield of 5.3%, our price target […]

Essa Pharma names Peter Virsik as EVP, COO

Essa Pharma names Peter Virsik as EVP, COO

August 2, 2016 by · Leave a Comment 

Tweet Essa Pharma (NASDAQ:EPIX; TSX:EPI) has appointed Peter Virsik as executive vice-president and chief operating officer. Mr. Virsik will be responsible for leading Essa’s overall business development and corporate strategy as the company further advances a clinical development plan for its novel prostate cancer therapeutic, EPI-506. Mr. Virsik is a seasoned biopharmaceutical executive with over […]

Next Page »

Email Newsletters with Constant Contact
Google+